S Trumpp-Kallmeyer

Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

J Hoflack, S. Trumpp-Kallmeyer, M. Manning, 1995, The EMBO journal.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors.

J Hoflack, S. Trumpp-Kallmeyer, J. Hoflack, 1992, Journal of medicinal chemistry.

G-Protein coupled receptors: models, mutagenesis, and drug design.

C. Humblet, S. Trumpp-Kallmeyer, J. Bikker, 1998, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Three-dimensional models of neurotransmitter G-binding protein-coupled receptors.

J Hoflack, S. Trumpp-Kallmeyer, J. Hoflack, 1991, Molecular pharmacology.

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

D. Boschelli, D. W. Fry, S. Trumpp-Kallmeyer, 2000, Journal of medicinal chemistry.

Functional architecture of vasopressin/oxytocin receptors.

J Hoflack, N. Cotte, S. Trumpp-Kallmeyer, 1999, Journal of receptor and signal transduction research.

Re-evaluation of bacteriorhodopsin as a model for G protein-coupled receptors.

J Hoflack, S. Trumpp-Kallmeyer, J. Hoflack, 1994, Trends in pharmacological sciences.

The Binding Site of Neuropeptide Vasopressin V1a Receptor

J Hoflack, S. Trumpp-Kallmeyer, B. Mouillac, 1995, The Journal of Biological Chemistry.